Thermo Fisher's Q2 Earnings Beat Expectations; Raises FY21 Outlook


Thermo Fisher Scientific Inc's TMO Q2 revenues grew 34% Y/Y to $9.3 billion, beating the consensus of $8.8 billion. Organic revenue growth from the base business was 27%. COVID-19 response revenue was $1.9 billion.

  • Adjusted EPS increased 44% to $5.60, ahead of the consensus of $5.49 
  • Adjusted operating margin expanded from 27% a year ago to 29%.
  • Revenue from Life Sciences Solutions Segment grew 37% to $3.56 billion, Analytical Instruments Segment up 41% to $1.48 billion, Specialty Diagnostics Segment increased 25% to $1.24 billion, and Laboratory Products and Services Segment was up 29% to $3.58 billion.
  • FY21 Guidance: Thermo Fisher is raising its revenue guidance by $300 million to $35.9 billion (consensus 35.7 billion), resulting in 11% revenue growth over 2020. 
  • It bumps up adjusted EPS guidance by $0.10 to $22.07 (consensus $22.12), representing 13% growth year over year.
  • Price Action: TMO shares closed at $530.28 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!